ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2016 American Transplant Congress

    Zero and One Mismathing for HLA DR10,14,16 Produces Increased Kidney Graft Survival.

    J. Cicciarelli,1,2 Y. Cho,2 M. Altrich,1 N. Kasahara,1,3 N. Lemp.1

    1Viracor-IBT HLA Lab, Viracor-IBT Laboratories, Los Angeles, CA; 2USC Keck School of Medicine, Los Angeles, CA; 3University of Miami, Miami, FL.

    Aims: HLA DR matching has shown measureable significant effects in kidney graft survival. Part and parcel of this association is the HLA Class II allele…
  • 2016 American Transplant Congress

    Clinical Outcome of Elderly Living Kidney Donors: A Single-Center Study in Japan.

    J. Hasegawa, K. Unagami, M. Okumi, K. Omoto, M. Inui, H. Ishida, K. Tanabe.

    Urology, Tokyo Women's Medical University, Tokyo, Japan.

    Background: Previous studies and current guidelines have suggested that elderly persons can be living kidney donors; however, reports on elderly donors >70 years old are…
  • 2016 American Transplant Congress

    Comparison of Efficacy and Safety of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus.

    P. Gatault,1 N. Kamar,2 M. Buchler,1 C. Colosio,3 D. Bertrand,4 A. Durrbach,5 L. Albano,6 J. Rivalan,7 M. Essig,8 Y. Le Meur,9 N. Bouvier,10 B. Charpentier,5 E. Thervet,11 L. Rostaing,2 Y. Lebranchu.1

    1Service de Transplantation rénale, CHRU, Tours, France; 2Service de Transplantation Rénale, CHU, Toulouse, France; 3Service de Transplantation Rénale, CHU, Reims, France; 4Service Transplantation Rénale, CHU, Rouen, France; 5Service de Transplantation Rénale, APHP, Kremlin Bicêtre, France; 6Service de Transplantation Rénale, CHU, Nice, France; 7Service de Transplantation Rénale, CHU, Rennes, France; 8Service de Transplantation Rénale, CHU, Limoges, France; 9Service de Transplantation Rénale, CHU, Brest, France; 10Service de Transplantation Rénale, CHU, Caen, France; 11Service de Néphrologie, APHP, Centre Européen Georges Pompidou, Boulogne-Billancourt, France.

    Introduction. The aim of the study was to determine the efficacy and safety balance of 2 different doses of tacrolimus extended-release (TacER) in kidney transplant…
  • 2016 American Transplant Congress

    Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.

    W. Arns,1 A. Huppertz,1 T. Rath,1 S. Ziefle,1 L. Rump,1 A. Hansen,1 D. Baeumer,2 K. Budde,1 L. Lehner,1 T. Klein,1 P. Schenker.1

    1SparTacus Study Group, Cologne, Germany; 2Novartis Pharma GmbH, Nuernberg, Germany.

    Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx)…
  • 2016 American Transplant Congress

    A Comparative Intention-to-Treat Analysis of Liver Transplantation for HCC – Living Donor Liver Transplant vs. Deceased Donor Liver Transplant.

    K. Tomiyama, N. Goldaracena, A. Barbas, M. Dib, G. Levy, L. Lilly, A. Ghanekar, I. McGilvray, E. Renner, M. Bhat, M. Selzner, M. Cattral, N. Selzner, P. Greig, D. Grant, G. Sapisochin.

    Multi-Organ Transplant Program, University of Toronto, Toronto, ON, Canada.

    IntroductionLiving donor liver transplantation (LDLT) can reduce waiting times and potentially decrease drop-out rates for cirrhotic patients with HCC. However, it has also been reported…
  • 2016 American Transplant Congress

    Which Is the Predictable Values of Post-Transplant Hepatocellular Carcinoma Recurrence in Patients Received Down Staging Therapy or Bridging Therapy?

    S. Song, J. Lee, S.-K. Kwon, J. Lee, J. Lee, D. Han, G. Choi, M. Kim, J. Choi, S. Kim, D. Joo.

    Department of Surgery and The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea.

    Introduction: Liver transplantation (LT) is one of the best treatment for small hepatocellular carcinoma (HCC) in patients with liver cirrhosis. However, many patients do not…
  • 2016 American Transplant Congress

    Impact of Ideal Body Weight vs. Actual Body Weight for the Prediction of Small for Size Syndrome and Graft Loss After Living Donor Liver Transplantation.

    M. Dib, N. Goldaracena, A. Barbas, M. Marquez, N. Alotaiby, G. Sapisochin, M. Cattral, L. Lilly, I. McGilvray, E. Renner, P. Greig, A. Ghanekar, N. Selzner, M. Selzner, D. Grant.

    Transplantation, Toronto General Hospital, Toronto, ON, Canada.

    Introduction: We compared the impact of estimating graft to recipient body weight ratio (GBWR) with actual body weight (ABW) and ideal body weight (IBW) on…
  • 2016 American Transplant Congress

    Predicting Late Medication Non-Adherence in Adult Kidney Transplant Recipients.

    D. Taber, A. Posadas, A. Chokkalingam, R. Browning, N. Salazar, M. Kamel, R. Pullalarevu, B. Kadri, K. Chavin, T. Srinivas, P. Baliga.

    MUSC, Charleston, SC.

    Background: Medication non-adherence (MNA) is a significant contributor to late graft loss in kidney transplant recipients. The aim of this study was to develop and…
  • 2016 American Transplant Congress

    Impact of Allograft Dysfunction and Early Low Grade Proteinuria on Survival in Expanded Criteria Donor Kidney Transplant Recipients.

    V. López, M. Cabello, P. Ruiz, C. Jironda, D. Burgos, M. González-Molina, D. Hernández.

    Nephrology, Hospital Regional de Málaga, Málaga, Spain.

    Introduction. Recent studies have demonstrated a relationship between low-grade proteinuria and worse graft survival, but this has not been fully studied in expanded criteria donor…
  • 2016 American Transplant Congress

    Can We Predict New-Onset Diabetes After Transplantation Previously?

    R. Imamura,1 K. Tsutahara,2 S. Nakazawa,1 Y. Kakuta,1 T. Abe,1 T. Takao,2 N. Ichimaru,3 S. Yamaguchi,2 S. Takahara,3 N. Nonomura.1

    1Urology, Osaka University Graduate School of Medicine, Suita, Japan; 2Urology, Osaka General Medical Center, Osaka, Japan; 3Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Suita, Japan.

    Objectives: New-onset diabetes after transplantation (NODAT), one of the important complications after kidneytransplantation, leads to reduce graft survival rate and increase patient morbidity and mortality.…
  • « Previous Page
  • 1
  • …
  • 132
  • 133
  • 134
  • 135
  • 136
  • …
  • 180
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences